share_log

NexImmune | 424B5: Prospectus

SEC announcement ·  Feb 5 16:41
Summary by Moomoo AI
NexImmune, Inc. has announced the offering of 117,000 shares of its common stock at a purchase price of $12.05 per share to an institutional investor, as detailed in a securities purchase agreement dated February 2, 2024. Additionally, the company is offering pre-funded warrants to purchase up to 187,731 shares of common stock to the same purchaser, in lieu of common stock that would result in the purchaser owning more than 9.99% of NexImmune's outstanding common stock post-transaction. Each pre-funded warrant is exercisable for one share of common stock at a nominal exercise price of $0.001 per share and is immediately exercisable. The offering also includes a concurrent private placement of common stock warrants to purchase up to 304,731 shares of common stock, which are...Show More
NexImmune, Inc. has announced the offering of 117,000 shares of its common stock at a purchase price of $12.05 per share to an institutional investor, as detailed in a securities purchase agreement dated February 2, 2024. Additionally, the company is offering pre-funded warrants to purchase up to 187,731 shares of common stock to the same purchaser, in lieu of common stock that would result in the purchaser owning more than 9.99% of NexImmune's outstanding common stock post-transaction. Each pre-funded warrant is exercisable for one share of common stock at a nominal exercise price of $0.001 per share and is immediately exercisable. The offering also includes a concurrent private placement of common stock warrants to purchase up to 304,731 shares of common stock, which are not registered under the Securities Act and are being offered under an exemption. The common stock is listed on The Nasdaq Capital Market under the symbol 'NEXI.' The last reported sale price of NexImmune's common stock was $15.19 per share as of February 1, 2024. The securities offered are expected to be delivered on or about February 6, 2024, subject to customary closing conditions.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more